Skin cancer: FDA approves Libtayo, first treatment for cutaneous squamous cell carcinoma
by Press Release from Outbreak News Today on (#3ZTC4)
The U.S. Food and Drug Administration today approved Libtayo (cemiplimab-rwlc) injection for intravenous use for the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC who are not candidates for curative surgery or curative radiation. This is the first FDA approval of a drug specifically for advanced CSCC. Libtayo works ["]
The post Skin cancer: FDA approves Libtayo, first treatment for cutaneous squamous cell carcinoma appeared first on Outbreak News Today.